DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)

Completed

Conditions: Multiple Myeloma

Interventions: Other: No Intervention

First Posted Date: 2021-04-12

Last Posted Date: 2024-07-24

Lead Sponsor: Takeda

Target Recruit Count: 191

Registration Number: NCT04840680

Locations: 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷
Keimyung University Dongsan Hospital, Daegu, Korea, Republic of

and more 17 locations

A Study of Prucalopride in Breastfeeding Women With Constipation

Recruiting

Conditions: Chronic Idiopathic Constipation (CIC)

Interventions: Other: No Intervention

First Posted Date: 2021-04-09

Last Posted Date: 2025-01-23

Lead Sponsor: Takeda

Target Recruit Count: 12

Registration Number: NCT04838522

Locations: 🇺🇸
University of California San Diego, La Jolla, California, United States

A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma

Active, not recruiting

Conditions: Lymphoma

Interventions: Other: No Intervention

First Posted Date: 2021-04-08

Last Posted Date: 2025-01-27

Lead Sponsor: Takeda

Target Recruit Count: 1000

Registration Number: NCT04837222

Locations: 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

and more 28 locations

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-994 Oral Tablet
Drug: [14C]TAK-994 Intravenous Infusion
Drug: [14C]TAK-994 Oral Suspension

First Posted Date: 2021-04-06

Last Posted Date: 2021-06-29

Lead Sponsor: Takeda

Target Recruit Count: 6

Registration Number: NCT04833049

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

Bioavailability and Food Effect Study of Two Formulations of TAK-906

Phase 1

Withdrawn

Conditions: Healthy Volunteers

Interventions: Drug: TAK-906

First Posted Date: 2021-04-05

Last Posted Date: 2022-03-24

Lead Sponsor: Takeda

Registration Number: NCT04831502

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study of TAK-994 in Adults With Narcolepsy

Phase 2

Terminated

Conditions: Narcolepsy Type 1 (NT 1)

Interventions: Drug: TAK-994
Drug: Placebo

First Posted Date: 2021-03-29

Last Posted Date: 2023-12-26

Lead Sponsor: Takeda

Target Recruit Count: 26

Registration Number: NCT04820842

Locations: 🇺🇸
Raleigh Neurology Associates,300209729, Raleigh, North Carolina, United States
🇺🇸
Fort Wayne Neurological Center 150711262, Fort Wayne, Indiana, United States
🇫🇮
Turku University Hospital, Turku, Finland

and more 67 locations

A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Phase 4

Active, not recruiting

Conditions: Crohn's Disease

Interventions: Other: CDPATH™
Other: Blood Draw

First Posted Date: 2021-03-22

Last Posted Date: 2025-01-15

Lead Sponsor: Takeda

Target Recruit Count: 200

Registration Number: NCT04809363

Locations: 🇺🇸
Grand Teton Research Group, PLL, Idaho Falls, Idaho, United States
🇺🇸
UMASS Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸
Gastro Center of Maryland, Columbia, Maryland, United States

and more 39 locations

A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease

Phase 4

Completed

Conditions: Ulcerative Colitis
Crohn Disease

Interventions: Drug: Vedolizumab IV

First Posted Date: 2021-03-18

Last Posted Date: 2025-02-12

Lead Sponsor: Takeda

Target Recruit Count: 150

Registration Number: NCT04804540

Locations: 🇮🇳
Banglore Medical College & Research Institute, Bangalore, Karnatka, India
🇮🇳
Deccan College of Medical Sciences, Hyderabad, India
🇮🇳
Asian Institute of Gastroenterology, Hyderabad, Telangana, India

and more 14 locations

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Cabozantinib

First Posted Date: 2021-03-18

Last Posted Date: 2025-04-11

Lead Sponsor: Takeda

Target Recruit Count: 388

Registration Number: NCT04804813

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis

Active, not recruiting

Conditions: Crohn Disease
Inflammatory Bowel Diseases
Colitis, Ulcerative

First Posted Date: 2021-03-16

Last Posted Date: 2025-03-27

Lead Sponsor: Takeda

Target Recruit Count: 600

Registration Number: NCT04799496

Locations: 🇰🇷
Soon Chunhyang University Hospital Bucheon, Bucheon, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Inje University Haeundae Paik Hospital, Busan, Korea, Republic of

and more 40 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy